Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
telisotuzumab adizutecan + fluorouracil + leucovorin + panitumumab
- Development stage
- Phase 2
- Lead developer
- AbbVie
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is an investigational combination regimen of **telisotuzumab adizutecan** (ABBV-400), an antibody-drug conjugate targeting c-Met, combined with **fluorouracil** (5-FU), a pyrimidine antimetabolite, **leucovorin** (folinic acid), and **panitumumab**, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR). This combination is currently studied for metastatic colorectal cancer (mCRC), aiming to improve response rates by simultaneously targeting c-Met and EGFR pathways along with standard chemotherapy modulation. Telisotuzumab adizutecan delivers a cytotoxic payload to c-Met-expressing tumor cells, while panitumumab blocks EGFR signaling; fluorouracil and leucovorin inhibit thymidylate synthase and enhance chemotherapy efficacy[3][4].
- Other names
- telisotuzumab adizutecan + 5-fluorouracil + leucovorin + panitumumabtelisotuzumab adizutecan + 5-FU + LV + panitumumab
02
Targets
DHFR (Dihydrofolate reductase)EGFR (Epidermal growth factor receptor)MET (Mesenchymal-epithelial transition factor receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on telisotuzumab adizutecan + fluorouracil + leucovorin + panitumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on telisotuzumab adizutecan + fluorouracil + leucovorin + panitumumab.